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background: Transcatheter aortic valve replacement (TAVR) has emerged as an alternative for the treatment of inoperable or surgical high-risk 
patients with severe aortic stenosis (AS). Early TAVR devices have been limited by challenges with precise valve positioning, paravalvular leakage, 
stroke, bleeding, and vascular complications. The repositionable and fully retrievable Lotus Valve was designed to facilitate accurate positioning and 
minimize paravalvular leakage in these patients. The initial safety and performance of the valve were demonstrated in the REPRISE II CE-mark trial at 
the primary endpoint of 30 days, but longer-term follow-up with the full 120-patient cohort has not been reported.
methods: REPRISE II is a prospective, single-arm, multicenter study that was designed to assess the safety and performance of the LOTUS Valve 
System in symptomatic patients aged ≥70 years with severe calcific AS who are at high surgical risk. The primary device performance endpoint was 
mean aortic valve pressure gradient at 30 days post-procedure, as assessed by an independent core laboratory. The primary safety endpoint was 
30-day all-cause mortality.
results: Among 120 enrolled patients, 100% were successfully implanted with a LOTUS valve. Of these, 57% (68/120) were female, with a mean 
age of 84.4±5.3 years. The mean STS Score was 7.1±4.6, mean euroSCORE II was 6.9±5.8, and 26% had medically treated diabetes. Baseline 
aortic valve area was 0.7±0.2 cm2, and the mean aortic valve pressure gradient was 46.4±15.0 mmHg. We have previously reported (Meredith et 
al. TCT 2013) that the 30-day mean aortic valve pressure gradient was 11.5±5.2 mmHg, which was significantly less than the performance goal of 
18 mmHg (P<0.001). There were low rates of overall mortality (4.2%) and disabling stroke (1.7%) at 30 days, and 84% of patients had no or trace 
paravalvular regurgitation.
conclusion: The LOTUS valve successfully met the 30-day primary performance and safety endpoints of the trial in the REPRISE II CE-mark study, 
with negligible paravalvular regurgitation and low safety event rates. Three-month results for the full 120 patients will be available for the first time 
at ACC 2014.
